- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
March 16, 2023Second Circuit Affirms Record $5.6 Billion Recovery in Antitrust Case
March 10, 2023Robins Kaplan Announces $28 Million Settlement in Case Against For-Profit College’s Directors & Officers
March 9, 2023Robins Kaplan LLP Launches New Professional Development Program
March 19-22, 2023PLRB 2023 Claims Conference
March 29-30, 2023ACI Managed Care Disputes and Litigation
April 3, 2023Conference of Tribal Lending Commissioners
March 13, 2023The Antitrust Case that Could Reshape Professional Golf
February 22, 2023A World Without Noncompetes: Protecting Confidential Information and Trade Secrets
February 7, 2023When Monkey Business Slips Into Trademark Infringement
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Trial Court Rules In Favor of Novel Labs. Invalidating Three Patents and Federal Circuit Summarily Affirms
Represented Novel Laboratories, Inc., a pharmaceutical company seeking to market a generic version of Intermezzo®. Intermezzo® is a sublingual formulation of zolpidem indicated for middle-of-the-night insomnia. Following a 10-day bench trial, Chief Judge Linares found in favor of our client, ruling that the asserted claims of all three patents-in-suit were invalid as obvious. The Federal Circuit confirmed the invalidity findings in a summary affirmance. LMG Life Sciences named this case one of the Hatch-Waxman Impact Cases of the Year in 2016. Purdue Pharm. v. Actavis Elizabeth LLC, 15-1659 (Fed. Cir.); Purdue Pharm. Products LP v. Actavis Elizabeth LLC, 12-5311 (D.N.J.).
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.